AstraZeneca’s Stomach Cancer Drug Extends Overall Survival in Late-Stage Trial
AstraZeneca has reported encouraging results from a late-stage clinical trial of its experimental cancer drug, sonesitatug vedotin (Sone-Ve), which helped extend overall survival among patients with advanced stomach and related cancers.
According to results presented at the European Society for Medical Oncology (ESMO) Congress in Madrid on 25 October 2026, patients receiving Sone-Ve after at least two previous treatments had a median overall survival of 10 months, compared with 5 months for patients receiving their doctor’s choice of chemotherapy in the third-line and later treatment setting…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.